Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
Condition(s):Multiple SclerosisLast Updated:February 20, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple SclerosisLast Updated:February 20, 2024Active, not recruiting
Condition(s):Progressive Multiple SclerosisLast Updated:March 30, 2023Recruiting
Condition(s):Multiple Sclerosis, Primary ProgressiveLast Updated:July 30, 2021Completed
Condition(s):Multimorbidity; Polypharmacy; Other Diagnoses, Comorbidities, and ComplicationsLast Updated:August 6, 2020Completed
Condition(s):Multiple SclerosisLast Updated:March 6, 2024Recruiting
Condition(s):Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple SclerosisLast Updated:February 17, 2012Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:February 4, 2013Completed
Condition(s):Primary Spontaneous PneumothoraxLast Updated:October 18, 2021Unknown status
Condition(s):Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Antibiotic ProphylaxisLast Updated:March 27, 2019Completed
Condition(s):Primary Progressive Multiple SclerosisLast Updated:June 14, 2017Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.